EXAGEN INC (XGN)
US30068X1037 - Common Stock
Exagen Inc. Announces Changes to the Board of Directors
Exagen Inc. Announces Changes to the Board of Directors
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced...
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023
XGN stock results show that Exagen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported...
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results...
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...
Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS
Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.
Exagen reaffirms FY23 revenue of at least $50M (NASDAQ:XGN)
The commercial-stage diagnostics firm Exagen (XGN) announces preliminary financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select...
Exagen files for a $150M mixed shelf offering (NASDAQ:XGN)
Exagen (XGN) files mixed shelf offering prospectus to raise $150M; not an offer to sell securities.
Exagen Inc. Reports Strong Third Quarter 2023 Results
Exagen Inc. Reports Strong Third Quarter 2023 Results
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported...
Exagen licenses lupus nephritis biomarkers from Johns Hopkins (XGN)
Exagen (XGN) has entered into a licensing deal with Johns Hopkins for the development of patented biomarkers for the management of lupus nephritis. Read more here.
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins...
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial...